DE60321775D1 - Carbaminsäurederivate enthaltend eine piperazin verknüpfung als hdac-inhibitoren - Google Patents

Carbaminsäurederivate enthaltend eine piperazin verknüpfung als hdac-inhibitoren

Info

Publication number
DE60321775D1
DE60321775D1 DE60321775T DE60321775T DE60321775D1 DE 60321775 D1 DE60321775 D1 DE 60321775D1 DE 60321775 T DE60321775 T DE 60321775T DE 60321775 T DE60321775 T DE 60321775T DE 60321775 D1 DE60321775 D1 DE 60321775D1
Authority
DE
Germany
Prior art keywords
acid derivatives
hdac inhibitors
piperazine compound
derivatives contain
carboxic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60321775T
Other languages
English (en)
Inventor
Clare J Watkins
Maria-Rosario Romero-Martin
James Ritchie
Paul W Finn
Ivars Kalvinsh
Einars Loza
Klara Dikovska
Igor Starchenkov
Daina Lolya
Vija Gailite
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Topotarget UK Ltd
Original Assignee
Topotarget UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Topotarget UK Ltd filed Critical Topotarget UK Ltd
Application granted granted Critical
Publication of DE60321775D1 publication Critical patent/DE60321775D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/74Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/42One nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182Radicals derived from carboxylic acids
    • C07D295/185Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182Radicals derived from carboxylic acids
    • C07D295/192Radicals derived from carboxylic acids from aromatic carboxylic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26Sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D317/00Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/58Radicals substituted by nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/60Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Pyridine Compounds (AREA)
  • Indole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
DE60321775T 2002-04-03 2003-04-03 Carbaminsäurederivate enthaltend eine piperazin verknüpfung als hdac-inhibitoren Expired - Lifetime DE60321775D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36933702P 2002-04-03 2002-04-03
PCT/GB2003/001463 WO2003082288A1 (en) 2002-04-03 2003-04-03 Carbamic acid compounds comprising a piperazine linkage as hdac inhibitors

Publications (1)

Publication Number Publication Date
DE60321775D1 true DE60321775D1 (de) 2008-08-07

Family

ID=28675576

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60321775T Expired - Lifetime DE60321775D1 (de) 2002-04-03 2003-04-03 Carbaminsäurederivate enthaltend eine piperazin verknüpfung als hdac-inhibitoren

Country Status (13)

Country Link
US (3) US7629343B2 (de)
EP (1) EP1492534B1 (de)
JP (1) JP4606027B2 (de)
AT (1) ATE399012T1 (de)
AU (1) AU2003229883B2 (de)
BR (1) BR0308908A (de)
CA (1) CA2479906C (de)
DE (1) DE60321775D1 (de)
ES (1) ES2309313T3 (de)
MX (1) MXPA04009490A (de)
NO (1) NO329942B1 (de)
NZ (1) NZ536116A (de)
WO (1) WO2003082288A1 (de)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7517884B2 (en) 1998-03-30 2009-04-14 Kalypsys Inc. Sulfonyl-substituted bicyclic compounds as modulators of PPAR
BR0307599A (pt) 2002-03-13 2005-02-01 Janssen Pharmaceutica Nv Derivados de sulfonilamino como inibidores de histona deacetilase
NZ534833A (en) 2002-03-13 2006-07-28 Janssen Pharmaceutica Nv Piperazinyl-, piperidinyl- and morpholinyl-derivatives as novel inhibitors of histone deacetylase (HDAC)
ATE521592T1 (de) 2002-03-13 2011-09-15 Janssen Pharmaceutica Nv Histone-deacetylase-inhibitoren
DE60321548D1 (de) 2002-03-13 2008-07-24 Janssen Pharmaceutica Nv Carbonylamino- derivativate als neue inhibitoren von histone deacetylase
AU2003229883B2 (en) * 2002-04-03 2009-06-11 Topotarget Uk Limited Carbamic acid compounds comprising a piperazine linkage as HDAC inhibitors
TW200418806A (en) 2003-01-13 2004-10-01 Fujisawa Pharmaceutical Co HDAC inhibitor
AU2004215624B2 (en) 2003-02-25 2011-06-02 Topotarget Uk Limited Hydroxamic acid compounds comprising a bicyclic heteroaryl group as HDAC inhibitors
EP1694329A4 (de) * 2003-11-26 2009-06-03 Aton Pharma Inc Diamin- und iminodiessigsäure-hydroxaminsäure-derivate
GB0401876D0 (en) 2004-01-28 2004-03-03 Vereniging Het Nl Kanker I New use for cancer antigen
CN1997625A (zh) * 2004-07-12 2007-07-11 默克公司 组蛋白脱乙酰基酶抑制剂
ME01058B (me) 2004-07-28 2012-10-20 Janssen Pharmaceutica Nv Supstituisani derivati propenil piperazina kao novi inhibitori histonske deacetilaze
JP4948403B2 (ja) 2004-07-28 2012-06-06 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ヒストン・デアセチラーゼの新インヒビターとしての置換インドリルアルキルアミノ誘導体
PT1776358E (pt) * 2004-07-28 2009-08-13 Janssen Pharmaceutica Nv Derivados de propenilpiperazina substituída como novos inibidores de histona-desacetilase
GB2417682A (en) * 2004-08-18 2006-03-08 Univ East Anglia Histone deacetylse inhibitor for treating connective tissue disorders
ES2682282T3 (es) 2004-10-29 2018-09-19 Kalypsys, Inc. Compuestos bicíclicos sustituidos con sulfonilo como moduladores de PPAR
JPWO2006082834A1 (ja) * 2005-02-02 2008-06-26 興和株式会社 ケラチノサイト増殖に起因する疾患の予防・治療剤
ITFI20050041A1 (it) * 2005-03-15 2006-09-16 Menarini Internat Operations Luxembourg Sa Idrossammati come inibitori dell'istone deacelitasi, loro preparazione e formulazioni farmaceutiche che li contengono
GB0509223D0 (en) 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Enzyme inhibitors
GB0509225D0 (en) 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Inhibitors of enzymatic activity
SI1901729T1 (sl) 2005-05-13 2012-05-31 Topotarget Uk Ltd Farmacevtske formulacije HDAC inhibitorjev
CA2605272C (en) 2005-05-18 2013-12-10 Janssen Pharmaceutica N.V. Substituted aminopropenyl piperidine or morpholine derivatives as novel inhibitors of histone deacetylase
US7732475B2 (en) 2005-07-14 2010-06-08 Takeda San Diego, Inc. Histone deacetylase inhibitors
EP2258358A3 (de) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenese mit Acetylcholinesterasehemmer
WO2007025177A2 (en) 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP1996550A2 (de) * 2005-09-27 2008-12-03 Novartis AG Carxoxyamin-zusammensetzungen und ihre verwendung bei der behandlung von hdac-abhängigen krankheiten
WO2007045962A2 (en) * 2005-10-18 2007-04-26 Orchid Research Laboratories Limited Novel hdac inhibitors
EP2377530A3 (de) 2005-10-21 2012-06-20 Braincells, Inc. Modulation von Neurogenese durch PDE-Hemmung
AU2006305769B2 (en) 2005-10-25 2012-06-14 Kalypsys, Inc. Salts of modulators of PPAR and methods of treating metabolic disorders
DK1943232T3 (da) 2005-10-27 2011-08-29 Janssen Pharmaceutica Nv Kvadratsyrederivater som inhibitorer af histondeacetylase
US20070112017A1 (en) 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
WO2007054719A2 (en) 2005-11-10 2007-05-18 Topotarget Uk Limited Histone deacetylase (hdac) inhibitors (pxdlol) for the treatment of cancer alone or in combination with chemotherapeutic agent
EP1968962A2 (de) 2005-12-14 2008-09-17 Amgen Inc. Heterocyclische diazasulfonamidderivate und anwendungen davon
EP1979327A1 (de) 2006-01-19 2008-10-15 Janssen Pharmaceutica, N.V. Pyridin- und pyrimidinderivate als inhibitoren von histondeacetylase
AU2007206950B2 (en) 2006-01-19 2012-02-02 Janssen Pharmaceutica N.V. Substituted indolyl-alkyl-amino-derivatives as inhibitors of histone deacetylase
JP5247470B2 (ja) 2006-01-19 2013-07-24 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ヒストンデアセチラーゼのインヒビターとしてのピリジン及びピリミジン誘導体
PL1981874T3 (pl) 2006-01-19 2009-10-30 Janssen Pharmaceutica Nv Pochodne aminofenylowe jako nowe inhibitory deacetylazy histonowej
ES2402213T3 (es) 2006-01-19 2013-04-29 Janssen Pharmaceutica N.V. Derivados de piridina y pirimidina como inhibidores de histona desacetilasa
ATE539073T1 (de) 2006-01-19 2012-01-15 Janssen Pharmaceutica Nv Heterocyclylalkylderivate als neue inhibitoren von histondeacetylase
RU2008135979A (ru) 2006-02-07 2010-03-20 Астеллас Фарма Инк. (Jp) Соединения гидроксиакрилаимда
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
US7678808B2 (en) 2006-05-09 2010-03-16 Braincells, Inc. 5 HT receptor mediated neurogenesis
EP2377531A2 (de) 2006-05-09 2011-10-19 Braincells, Inc. Neurogenese mittels Angiotensin-Modulation
MX2009002496A (es) 2006-09-08 2009-07-10 Braincells Inc Combinaciones que contienen un derivado de 4-acilaminopiridina.
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
GB0619753D0 (en) 2006-10-06 2006-11-15 Chroma Therapeutics Ltd Enzyme inhibitors
EA017198B1 (ru) 2006-10-30 2012-10-30 Хрома Терапьютикс Лтд. Гидроксаматы в качестве ингибиторов гистон-деацетилазы
WO2008091863A1 (en) 2007-01-23 2008-07-31 Kalypsys, Inc. Sulfonyl-substituted bicyclic compounds as ppar modulators for the treatment of non-alcoholic steatohepatitis
CA2700173C (en) 2007-09-25 2016-10-11 Topotarget Uk Limited Methods of synthesis of certain hydroxamic acid compounds
WO2009079375A1 (en) 2007-12-14 2009-06-25 Georgetown University Histone deacetylase inhibitors
EP2274301B1 (de) 2008-03-27 2012-09-26 Janssen Pharmaceutica, N.V. Azabicyclohexylsubstituierte indolylalkylaminoderivate als neue inhibitoren von histondeacetylase
WO2010001366A1 (en) * 2008-07-04 2010-01-07 Institut National De La Sante Et De La Recherche Medicale (Inserm) Piperazines derivatives as proteasome modulators
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
GB0903480D0 (en) 2009-02-27 2009-04-08 Chroma Therapeutics Ltd Enzyme Inhibitors
US9045445B2 (en) 2010-06-04 2015-06-02 Albany Molecular Research, Inc. Glycine transporter-1 inhibitors, methods of making them, and uses thereof
WO2012027495A1 (en) 2010-08-27 2012-03-01 University Of The Pacific Piperazinylpyrimidine analogues as protein kinase inhibitors
WO2012087889A2 (en) * 2010-12-20 2012-06-28 The Ohio State University Research Foundation Dna methylation inhibitors
CN102260225B (zh) * 2011-06-02 2013-08-21 蒋杰 用于抑制肿瘤转移和肿瘤血管生长的苯基哌嗪类衍生物
WO2013066831A1 (en) * 2011-10-31 2013-05-10 Glaxosmithkline Llc Compounds and methods
AU2012362726A1 (en) * 2011-12-29 2014-07-24 Pharmacyclics Llc Cinnamic acid hydroxyamides as inhibitors of histone deacetylase 8
ES2852054T3 (es) 2013-03-15 2021-09-10 Global Blood Therapeutics Inc Compuestos y usos de los mismos para la modulación de hemoglobina
AU2014337102B2 (en) * 2013-10-18 2019-02-28 The General Hospital Corporation Imaging histone deacetylases with a radiotracer using positron emission tomography
EA202092627A1 (ru) 2013-11-18 2021-09-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
JP6392888B2 (ja) * 2014-03-12 2018-09-19 チョン クン ダン ファーマシューティカル コーポレーション ヒストン脱アセチル化酵素6阻害剤としての新規化合物およびこれを含む薬剤学的組成物
EP3223816B1 (de) 2014-11-26 2020-04-22 The J. David Gladstone Institutes Verfahren zur behandlung einer cytomegalovirusfektion
CN107531660A (zh) 2015-03-13 2018-01-02 福马治疗股份有限公司 作为HDAC8抑制剂的α‑肉桂酰胺化合物和组合物
JP6507267B2 (ja) 2015-05-22 2019-04-24 チョン クン ダン ファーマシューティカル コーポレーション 選択的ヒストンデアセチラーゼ阻害剤としてのヘテロ環状アルキル誘導体化合物及びこれを含有する薬剤学的組成物
US10357493B2 (en) 2017-03-10 2019-07-23 Selenity Therapeutics (Bermuda), Ltd. Metalloenzyme inhibitor compounds
US20220154282A1 (en) 2019-03-12 2022-05-19 The Broad Institute, Inc. Detection means, compositions and methods for modulating synovial sarcoma cells
WO2022157499A1 (en) * 2021-01-20 2022-07-28 LightOx Limited Protected hdac (histone deacetylase) inhibitors

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5318964A (en) 1992-06-11 1994-06-07 Hoffmann-La Roche Inc. Hydroxamic derivatives and pharmaceutical compositions
JPH0775593A (ja) 1993-09-08 1995-03-20 Suntory Ltd 蛋白質の製造方法
JPH07278086A (ja) * 1993-11-08 1995-10-24 Terumo Corp ヒドロキサム酸誘導体およびそれを含有する医薬製剤
GB9501737D0 (en) 1994-04-25 1995-03-22 Hoffmann La Roche Hydroxamic acid derivatives
EP0827742A1 (de) 1996-09-04 1998-03-11 Vrije Universiteit Brussel Verwendung von Histondeacetylasehemmern zur Behandlung von Fibrose oder Zirrhose
YU34599A (sh) * 1997-01-23 2002-03-18 F. Hoffmann-La Roche Ag. Inhibitori sulfamid-metaloproteaze
US6696449B2 (en) * 1997-03-04 2004-02-24 Pharmacia Corporation Sulfonyl aryl hydroxamates and their use as matrix metalloprotease inhibitors
ES2206903T3 (es) 1997-03-04 2004-05-16 Monsanto Company Compuestos sulfonilicos divalentes de acido aril o heteroaril-hidroxamco.
US7115632B1 (en) 1999-05-12 2006-10-03 G. D. Searle & Co. Sulfonyl aryl or heteroaryl hydroxamic acid compounds
JP2001500533A (ja) 1997-07-10 2001-01-16 フアルマシア・エ・アツプジヨン・エツセ・ピー・アー マトリックスメタロプロテイナーゼ・インヒビター
IL135921A (en) 1997-11-12 2005-08-31 Darwin Discovery Ltd Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity
IL140982A0 (en) * 1998-07-21 2002-02-10 Warner Lambert Co Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions
EP1107953A1 (de) 1998-08-29 2001-06-20 British Biotech Pharmaceuticals Limited Hydoxamsäurederivate als proteinase-inhibitoren
GB9919776D0 (en) 1998-08-31 1999-10-27 Zeneca Ltd Compoujnds
US6492394B1 (en) 1998-12-22 2002-12-10 Syntex (U.S.A.) Llc Sulfonamide hydroxamates
RU2232751C2 (ru) 1998-12-22 2004-07-20 Ф.Хоффманн-Ля Рош Аг Производные сульфонамидов и фармацевтическая композиция
US6448250B1 (en) 1999-02-08 2002-09-10 G. D. Searle & Company Sulfamato hydroxamic acid metalloprotease inhibitor
AU3312100A (en) * 1999-03-22 2000-10-09 Darwin Discovery Limited Hydroxamic and carboxylic acid derivatives
KR20020009610A (ko) * 1999-05-12 2002-02-01 윌리암스 로저 에이 매트릭스 메탈로프로테아제 억제제로서의 히드록삼산 유도체
GB9911073D0 (en) 1999-05-12 1999-07-14 Darwin Discovery Ltd Hydroxamic and carboxylic acid derivatives
EP1202968A2 (de) 1999-08-10 2002-05-08 British Biotech Pharmaceuticals Limited Antibakterielle mittel
AU783504C (en) 1999-11-23 2006-08-03 Methylgene Inc. Inhibitors of histone deacetylase
GB9929979D0 (en) 1999-12-17 2000-02-09 Darwin Discovery Ltd Hydroxamic acid derivatives
US6852752B2 (en) * 1999-12-17 2005-02-08 Vicuron Pharmaceuticals Inc. Urea compounds, compositions and methods of use and preparation
US6797820B2 (en) * 1999-12-17 2004-09-28 Vicuron Pharmaceuticals Inc. Succinate compounds, compositions and methods of use and preparation
CA2393825A1 (en) * 1999-12-17 2001-06-21 Versicor, Inc. Novel succinate compounds, compositions and methods of use and preparation
US6495677B1 (en) * 2000-02-15 2002-12-17 Kanda S. Ramasamy Nucleoside compounds
CN1404474A (zh) 2000-02-21 2003-03-19 阿斯特拉曾尼卡有限公司 芳基哌嗪和芳基哌啶及其作为金属蛋白酶抑制剂的应用
CA2409035A1 (en) 2000-05-15 2001-11-22 Darwin Discovery Limited Hydroxamic acid derivatives
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
AU2002230385A1 (en) 2000-09-25 2002-04-15 Questcor Pharmaceuticals, Inc. Peptide deformylase inhibitors
US7569724B2 (en) 2000-09-29 2009-08-04 Topotarget Uk Limited Carbamic acid compounds comprising an amide linkage as HDAC inhibitors
CA2423744C (en) 2000-09-29 2012-04-03 Prolifix Limited Hydroxamic acid compounds comprising a sulfonamide linkage as hdac inhibitors
GB0023983D0 (en) 2000-09-29 2000-11-15 Prolifix Ltd Therapeutic compounds
US6784173B2 (en) * 2001-06-15 2004-08-31 Hoffmann-La Roche Inc. Aromatic dicarboxylic acid derivatives
US6683078B2 (en) * 2001-07-19 2004-01-27 Pharmacia Corporation Use of sulfonyl aryl or heteroaryl hydroxamic acids and derivatives thereof as aggrecanase inhibitors
AU2003229883B2 (en) 2002-04-03 2009-06-11 Topotarget Uk Limited Carbamic acid compounds comprising a piperazine linkage as HDAC inhibitors

Also Published As

Publication number Publication date
NO329942B1 (no) 2011-01-24
ATE399012T1 (de) 2008-07-15
BR0308908A (pt) 2005-01-04
AU2003229883A1 (en) 2003-10-13
JP2005527556A (ja) 2005-09-15
EP1492534B1 (de) 2008-06-25
MXPA04009490A (es) 2005-06-08
US20080269237A1 (en) 2008-10-30
AU2003229883B2 (en) 2009-06-11
WO2003082288A1 (en) 2003-10-09
NO20044744L (no) 2004-11-02
CA2479906A1 (en) 2003-10-09
US7981895B2 (en) 2011-07-19
NZ536116A (en) 2007-01-26
US7629343B2 (en) 2009-12-08
EP1492534A1 (de) 2005-01-05
US20110275810A1 (en) 2011-11-10
ES2309313T3 (es) 2008-12-16
CA2479906C (en) 2011-02-08
US20050143385A1 (en) 2005-06-30
JP4606027B2 (ja) 2011-01-05

Similar Documents

Publication Publication Date Title
DE60321775D1 (de) Carbaminsäurederivate enthaltend eine piperazin verknüpfung als hdac-inhibitoren
BRPI0409227B8 (pt) "composto, composição farmacêutica, uso de um composto e processo para a preparação de um composto de fórmula (i)"
CY1120141T1 (el) Παραγωγο βενζαμιδιου ως αναστολεας απακετυλασης ιστονης με ισχυρη διαφοροποιητικη και αντιπολλαπλασιαστικη δραστικοτητα
ATE307810T1 (de) Imidazol-2-carbonsäureamid derivate als raf- kinase-inhibitoren
EA200401199A1 (ru) Ингибиторы гистондеацетилазы
BRPI0410727A (pt) composto, composição farmacêutica, e, uso de um composto
EA200700138A1 (ru) Замещённые индолильные алкиламинопроизводные в качестве новых ингибиторов гистондеацетилазы
EA200700143A1 (ru) Производные замещенного пропенилпиперазина в качестве новых ингибиторов гистондеацетилазы
MY142589A (en) Benzimidazole derivatives : preparation and pharmaceutical applications
DK1692097T3 (da) Tricykliske hydroxamat- og benzamidderivater, sammensætninger og fremgangsmåder
BR0212510A (pt) Inibidor de histona desacetilase, composto e composição
EA200700902A1 (ru) 3-ариламинопиридиновые производные
BRPI0506676A (pt) piridazinona uréias como antagonistas de integrinas alfa4
EA201370122A1 (ru) Фармацевтические составы, содержащие ингибиторы деацетилазы гистонов
BR0315580A (pt) Derivados de metileno uréia
ATE509920T1 (de) Quadratsäurederivate als inhibitoren von histondeacetylase
EP1817312A4 (de) Makrozyklische aminiopyridyl-beta-sekretase-hemmer zur behandlung von morbus alzheimer
BRPI0417858A (pt) composto, composição farmacêutica, e, uso de uma composição farmacêutica
NO20080650L (no) Forbindelser omfattende DMXAA for behandling av kreft
WO2007029036A3 (en) Amino acid derivatives as histone deacetylase (hdac) inhibitors
EP1975158A4 (de) Neue pyrrolderivate mit histondeacetylase-hemmwirkung
ATE373636T1 (de) Amidderivate als inhibitoren der enzymatischen aktivität von renin
EP1640380A4 (de) Histondeacetylaseinhibitor und verfahren zu dessen herstellung
DE60119514D1 (de) Amidderivate der 2-amino-3-hydroxy-4-tert-leucyl-amino-5-phenyl-pentansäure
DE602004019914D1 (de) Colchicosidanaloge

Legal Events

Date Code Title Description
8364 No opposition during term of opposition